Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

High-Sensitivity Troponin T Assay Picks Out Low-Risk Patients in US Emergency Departments

Todd Neale

December 14, 2017

News Conference News AHA 2017

Global Improvement in ACS Care Seen With Regional Clinical Pathway Implementation

Yael L. Maxwell

November 27, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2017

Shelley Wood

July 03, 2017

News Daily News

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Yael L. Maxwell

June 29, 2017

News Daily News

Smartphone App Mobilizes Members of the Public to Be Cardiac Arrest First Responders

Todd Neale

June 21, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Daily News

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

L.A. McKeown

April 17, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Daily News

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

L.A. McKeown

March 14, 2017

News Daily News

Mixed Clinical, Biomarker Score Might Boost CAD Risk Prediction

Yael L. Maxwell

March 03, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

Advertisement

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

High-Sensitivity Troponin T Assay Picks Out Low-Risk Patients in US Emergency Departments

Global Improvement in ACS Care Seen With Regional Clinical Pathway Implementation

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

TCTMD’s Top 10 Most Popular Stories for June 2017

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Smartphone App Mobilizes Members of the Public to Be Cardiac Arrest First Responders

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

Mixed Clinical, Biomarker Score Might Boost CAD Risk Prediction

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content